Anticipated $0.07 EPS for BioSyent Inc. (RX) on May, 24

May 16, 2018 - By Robert Reynolds

BioSyent Inc. (CVE:RX)’s quarterly earnings will be announced on May, 24., Zacks reports. Last year’s EPS was $0.06, while now analysts expect change of 16.67 % up from current $0.07 EPS. If EPS of $0.07 is announced the profit of V_RX could be $1.01 million giving it 36.11 P/E. Analysts at Wall Street see BioSyent Inc.’s -30.00 % negative EPS growth compared to $0.10 EPS for last quarter. Ticker’s shares touched $10.11 during the last trading session after 0.60% change.BioSyent Inc. has volume of 264 shares. Since May 17, 2017 RX has 0.00% and is . The stock underperformed the S&P 500 by 11.55%.

BioSyent Inc., a specialty pharmaceutical company, acquires or in-licenses, develops, and sells various pharmaceutical and other healthcare products in Canada and internationally.The firm is valued at $146.55 million. The Company’s products include FeraMAX 150, an oral hematinic for the prevention and treatment of iron deficiency anaemia; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; Proktis-M, a rectal suppository to help healing of the anus and rectum; Aguettant System for pre-filled syringes that are used for various injectable medications in hospital and acute care settings; and Cysview for the detection and management of papillary non-muscle invasive bladder cancer.28.08 is the P/E ratio. The company's products also comprise Cathejell Jelly 2% indicated for surface anesthesia and lubrication for various procedures, including male and female cystoscopies, catheterizations, and other endourethral operations; and endoscopies, proctoscopies, rectoscopies, and tracheal intubations, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.